[go: up one dir, main page]

BR9815140A - "derivados de 2-aril-8-oxodidropurina, processo para a sua produção, composições medicinais contendo os mesmos, e seus intermediários" - Google Patents

"derivados de 2-aril-8-oxodidropurina, processo para a sua produção, composições medicinais contendo os mesmos, e seus intermediários"

Info

Publication number
BR9815140A
BR9815140A BR9815140-1A BR9815140A BR9815140A BR 9815140 A BR9815140 A BR 9815140A BR 9815140 A BR9815140 A BR 9815140A BR 9815140 A BR9815140 A BR 9815140A
Authority
BR
Brazil
Prior art keywords
aryl
derivatives
production
compositions containing
medicinal compositions
Prior art date
Application number
BR9815140-1A
Other languages
English (en)
Inventor
Teruya Murata
Kaoru Masumoto
Katsunori Kondo
Kiyoshi Furukawa
Makoto Oka
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of BR9815140A publication Critical patent/BR9815140A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE 2-ARIL-8-OXODIIDROPURINA, PROCESSO PARA A SUA PRODUçãO, COMPOSIçõES MEDICINAIS CONTENDO OS MESMOS, E SEUS INTERMEDIáRIOS" Derivados de 2-aril-8-oxodiidro purina representados pela fórmula geral (I) os seus sais por adição de ácido farmaceuticamente aceitáveis. Estes compostos são úteis como remédios e preventivos para doenças associadas com ansiedade (neurose, distúrbio psicofisiológico, distúrbio de ansiedade etc), doenças do sistema nervoso central tais como depressão e epilepsia e doenças circulatórias tais como angina pectoris e hipertensão. Na citada fórmula, A representa fenila opcionalmente substituído ou heteroarila opcionalmente substituído; e ou X ou Y representa [Q] : -CH (R³) CON (R¹) (R²).
BR9815140-1A 1997-12-03 1998-11-26 "derivados de 2-aril-8-oxodidropurina, processo para a sua produção, composições medicinais contendo os mesmos, e seus intermediários" BR9815140A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP35000097 1997-12-03
PCT/JP1998/005320 WO1999028320A1 (en) 1997-12-03 1998-11-26 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof

Publications (1)

Publication Number Publication Date
BR9815140A true BR9815140A (pt) 2000-10-10

Family

ID=18407561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815140-1A BR9815140A (pt) 1997-12-03 1998-11-26 "derivados de 2-aril-8-oxodidropurina, processo para a sua produção, composições medicinais contendo os mesmos, e seus intermediários"

Country Status (26)

Country Link
US (1) US6372740B1 (pt)
EP (1) EP1036794B1 (pt)
JP (1) JP3815966B2 (pt)
KR (1) KR100494347B1 (pt)
CN (1) CN1146566C (pt)
AR (1) AR017796A1 (pt)
AT (1) ATE248169T1 (pt)
AU (1) AU744014B2 (pt)
BR (1) BR9815140A (pt)
CA (1) CA2312885C (pt)
DE (1) DE69817611T2 (pt)
DK (1) DK1036794T3 (pt)
ES (1) ES2205574T3 (pt)
HU (1) HUP0004422A3 (pt)
ID (1) ID24929A (pt)
IL (1) IL135920A0 (pt)
NO (1) NO20002835L (pt)
NZ (1) NZ504457A (pt)
PL (1) PL191489B1 (pt)
PT (1) PT1036794E (pt)
RU (1) RU2223272C2 (pt)
SK (1) SK285703B6 (pt)
TR (1) TR200001600T2 (pt)
TW (1) TW502034B (pt)
WO (1) WO1999028320A1 (pt)
ZA (1) ZA9810490B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
CN1399632A (zh) * 1999-09-27 2003-02-26 小野药品工业株式会社 嘧啶衍生物、其制备方法和含有该化合物作为有效成分的药物
US6962921B2 (en) * 2000-07-31 2005-11-08 Dainippon Pharmaceutical Co., Ltd. Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
KR20060118398A (ko) * 2003-08-05 2006-11-23 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 이온 채널 억제제로서의 축합 피라미딘 화합물
EP1719761A4 (en) * 2004-02-23 2007-10-10 Dainippon Sumitomo Pharma Co NEW HETEROCYCLIC CONNECTION
US20080015196A1 (en) * 2004-04-16 2008-01-17 Neurogen Corporation Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands
FR2870239B1 (fr) * 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
RU2007140903A (ru) * 2005-04-05 2009-05-20 Фармакопия, Инк. (Us) Производные пурина и имидазопиридина для иммуносупрессии
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CN101454325A (zh) * 2006-03-09 2009-06-10 法马科皮亚公司 用于治疗代谢性疾病的8-杂芳基嘌呤mnk2抑制剂
WO2008043019A1 (en) * 2006-10-04 2008-04-10 Pharmacopeia, Inc 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
AR063142A1 (es) * 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ES2631003T3 (es) 2006-10-19 2017-08-25 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
JP2009007273A (ja) * 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8473571B2 (en) 2009-01-08 2013-06-25 Microsoft Corporation Synchronizing presentation states between multiple applications
ES2626246T3 (es) * 2009-09-09 2017-07-24 Sumitomo Dainippon Pharma Co., Ltd. Derivado de 8-oxodihidropurina
KR20120091240A (ko) 2009-10-26 2012-08-17 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물의 합성 및 정제 방법
JP2014076947A (ja) * 2011-02-03 2014-05-01 Dainippon Sumitomo Pharma Co Ltd ２−オキシ置換８−オキソジヒドロプリン誘導体
US20140301947A1 (en) 2011-06-06 2014-10-09 Imperial Innovations Limited Methods to predict binding affinity of tspo imaging agents to tspo
KR101978537B1 (ko) 2011-10-19 2019-05-14 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
SG10201604558SA (en) 2011-12-02 2016-07-28 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4 methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
JP6114317B2 (ja) 2012-02-24 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
CN102675315B (zh) * 2012-02-28 2015-04-01 中国人民解放军第四军医大学 含取代苯烷基的嘌呤类化合物和制备方法及应用
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EA201591327A1 (ru) 2013-01-16 2015-12-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
SG10201708111YA (en) 2013-04-17 2017-11-29 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
TWI631949B (zh) 2013-04-17 2018-08-11 標誌製藥公司 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
MX377267B (es) 2013-04-17 2025-03-07 Signal Pharm Llc Tratamiento de cáncer con dihidropirazino-pirazinas.
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
AU2016356694B2 (en) 2015-11-20 2021-07-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
BR112019027402A2 (pt) 2017-06-22 2020-07-07 Celgene Corporation tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b
WO2019155042A1 (en) 2018-02-12 2019-08-15 F. Hoffmann-La Roche Ag Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525595A1 (fr) 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
FR2582514B1 (fr) 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
DK273689A (da) 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
FR2632639B1 (fr) 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
US6083953A (en) 1994-07-28 2000-07-04 Syntex (U.S.A.) Inc. 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
EP0882727B9 (en) 1996-07-03 2005-06-15 Sumitomo Pharmaceuticals Company, Limited Novel purine derivatives
AU751710B2 (en) * 1997-04-22 2002-08-22 Neurocrine Biosciences Inc. CRF antagonistic thiophenopyridines
JP3814125B2 (ja) * 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬

Also Published As

Publication number Publication date
TW502034B (en) 2002-09-11
WO1999028320A1 (en) 1999-06-10
SK7972000A3 (en) 2001-03-12
NO20002835L (no) 2000-07-24
NO20002835D0 (no) 2000-06-02
HK1028769A1 (en) 2001-03-02
US6372740B1 (en) 2002-04-16
JP3815966B2 (ja) 2006-08-30
IL135920A0 (en) 2001-05-20
PL340925A1 (en) 2001-03-12
CA2312885C (en) 2008-01-29
ZA9810490B (en) 1999-05-20
AU1260499A (en) 1999-06-16
AR017796A1 (es) 2001-10-24
TR200001600T2 (tr) 2000-11-21
RU2223272C2 (ru) 2004-02-10
CN1146566C (zh) 2004-04-21
CN1284076A (zh) 2001-02-14
EP1036794A4 (en) 2001-12-12
EP1036794B1 (en) 2003-08-27
ATE248169T1 (de) 2003-09-15
KR100494347B1 (ko) 2005-06-13
HUP0004422A3 (en) 2001-10-29
ES2205574T3 (es) 2004-05-01
NZ504457A (en) 2001-12-21
DE69817611T2 (de) 2004-02-26
PT1036794E (pt) 2003-11-28
KR20010032686A (ko) 2001-04-25
EP1036794A1 (en) 2000-09-20
DE69817611D1 (de) 2003-10-02
CA2312885A1 (en) 1999-06-10
SK285703B6 (sk) 2007-06-07
DK1036794T3 (da) 2003-12-22
AU744014B2 (en) 2002-02-14
PL191489B1 (pl) 2006-05-31
HUP0004422A2 (hu) 2001-04-28
ID24929A (id) 2000-08-31

Similar Documents

Publication Publication Date Title
BR9815140A (pt) "derivados de 2-aril-8-oxodidropurina, processo para a sua produção, composições medicinais contendo os mesmos, e seus intermediários"
BR0009411A (pt) Composto de anilina substituìda, e, processo para a preparação e uso de compostos
PT83647B (pt) Processo para a preparacao de novos derivados de benzimidazole com actividade farmacologica e de composicoes farmaceuticas que os contem
BR9810021A (pt) Derivados 9-oxima-eritromicina
BR9808281A (pt) Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
BR9814592A (pt) "compostos azopolicìclicos condensados com arila"
FI906438A0 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten A-nor-steroidi-3-karboksyylihappojohdannaisten valmistamiseksi
DE3777544D1 (de) Glutaminsaeure-derivate, verfahren und zwischenprodukte zu ihrer herstellung und diese enthaltende pharmazeutische formulierungen.
EP0216743A3 (en) Galenical forms of verapamil, preparation thereof and medicaments containing them
BR0011700A (pt) Dinitrilas de ácido arilmalÈnico substituìdo como intermediários para a preparação de herbicidas
PT90034A (pt) Processo para a preparacao de tetra-hidroimidazo-{1,4}benzodiazepina-2-onas
BR9812062A (pt) Composto, uso deste, processo para prepará-lo, enanciÈmero único purificado, composição farmacêutica, e, processos para tratamento de bronquite crÈnica ou de doença pulmonar obstrutiva crÈnica em um indivìduo humano ou animal, e para tratamento de asma em um indivìduo humano ou animal
BR9910058A (pt) Compostos azapolicìclicos aril-condensados
EP0345671A3 (en) Cephem compounds and processes for preparation thereof
PT81246B (pt) Processo para a preparacao de pirazolo-piridino-amidas e dos seus derivados 7-n-oxidos e de composicoes farmaceuticas contendo estes compostos
DE69105786D1 (de) Harnstoffderivate, deren Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen.
BR9807406A (pt) Formulação farmacêutica, e, processo para a preparação das mesmas
PT80791A (fr) Procede de preparation de nouvelles phenyl-naphtiridines utiles notamment comme medicaments anti-ulceres
PT84680B (pt) Processo para a preparacao de derivados de 1,5-benzotiazepina e de composicoes farmaceuticas que os contem
ES2082882T3 (es) Procedimiento para la fabricacion de derivados de acidos-3-amino-2-(het)aroil-acrilicos.
DE3464244D1 (de) 1-(4'alkylsulfonylphenyl)-2-amino-1,3-propanediol n-substituted derivatives
DK526087D0 (da) Antikonvulsive aminosyrederivater
FI864970A0 (fi) Nya kristallina salter av aryloxi-propanolaminer, foerfarande foer deras framstaellning och deras anvaendning.
KR880009938A (ko) 9-아미노-1,4-에타노-1,2,3,4-테트라하이드로아크리딘, 그의 중간체, 제조방법 및 약제로서의 용도
BR9810622A (pt) 3-benzilpiperidinas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.